Ascendis Pharma A/S (ASND)

Ascendis Pharma Stock Forecast

Stock Price Forecast

The 14 analysts with 12-month price forecasts for Ascendis Pharma stock have an average target of 201.79, with a low estimate of 140 and a high estimate of 289. The average target predicts an increase of 30.46% from the current stock price of 154.68.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$140	$201.79	$200	$289
Change	-9.49%	+30.46%	+29.30%	+86.84%

Analyst Ratings

The average analyst rating for Ascendis Pharma stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	6	6	6	7	7	7
Buy	6	6	6	6	6	6
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	13	13	13	14	14	14

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jessica Fye JP Morgan	JP Morgan	Buy Maintains $168 → $200	Buy	Maintains	$168 → $200	+29.30%	Mar 18, 2025
Li Watsek Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $170 → $200	Buy	Maintains	$170 → $200	+29.30%	Feb 25, 2025
Josh Schimmer Evercore ISI Group	Evercore ISI Group	Buy Maintains $220 → $260	Buy	Maintains	$220 → $260	+68.09%	Feb 18, 2025
Paul Choi Goldman Sachs	Goldman Sachs	Strong Buy Maintains $200 → $225	Strong Buy	Maintains	$200 → $225	+45.46%	Feb 13, 2025
Jessica Fye JP Morgan	JP Morgan	Buy Maintains $167 → $168	Buy	Maintains	$167 → $168	+8.61%	Feb 13, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

577.78M

Increased by 58.89%

from 363.64M

Revenue Next Year

1.02B

Increased by 75.85%

from 577.78M

EPS This Year

-3.88

from -6.53

EPS Next Year

1.15

from -3.88

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Jan 1, 2023	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	6.95M	7.78M	51.17M	266.72M	363.64M	577.78M	1.02B	1.55B
Revenue Growth	-48.02%	11.87%	557.93%	421.20%	36.34%	58.89%	75.85%	52.46%
EPS	-8.28	-7.00	-10.40	-8.55	-6.53	-3.88	1.15	6.32
EPS Growth	-	-	-	-	-	-	-	450.32%
Forward PE	-	-	-	-	-	-	124.71	22.66
No. Analysts	-	-	-	-	-	17	17	11

Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	800.1M	1.6B	2.6B
Avg	577.8M	1.0B	1.5B
Low	473.5M	703.8M	1.1B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	120.0%	183.8%	153.5%
Avg	58.9%	75.8%	52.5%
Low	30.2%	21.8%	8.6%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-0.49	7.03	11.26
Avg	-3.88	1.15	6.32
Low	-6.17	-2.53	2.38

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	880.5%
Avg	-	-	450.3%
Low	-	-	107.3%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.